Abstract:17099 Background: Prolonged infusion of gemcitabine have shown increased levels of the active triphosphate metabolite that theorically could increase the response rate and toxicity. The objectives of this study were to evaluated the efficacy and safety of this combination of using gemcitabine as a rate infusion of 10 mg/m2 per min with carboplatin in front-line chemonaive patients with advanced NSCLC. Methods: Fifty-four chemonaive patients have been included. 44 were male and 10 female. Median age was 63 years (19–75). 13% had ECOG 0 and 53.7% ECOG 1 and 33.3% ECOG 2. 32 (59.2%) patients had adenocarcinoma, 13 (24.1%) squamous cell, 1 (1.9%) large cell carcinoma, and 8 (14.8%) others. Eight (14.8%) had stage IIIB and 46 (85.2%) stage IV. Treatment was consisted of 1200 mg/m2 gemcitabine given as a 2-hour continuous infusion (10 mg/m2 per min) on days 1 and 8 of each cycle an AUC 5 carboplatin as on day 1, repeating each cycle every 21 days. A total of 223 chemotherapy cycles were administered, with a median of 4 cycles per patient (range 1–6), and 15 (27.8%) patients received all six cycles. Results: Of the fifty-four patients enrolled, all were evaluated for toxicity (according to the WHO scale) and 51 assessed for response (according to the RECIST criteria), the overall response rate (ORR) was 41.2% (95% confidence interval, 28% to 57%), including two complete responses (CRs: 3.9%) and 19 partial responses (PRs: 37.3%). As per the intent-to-treat (ITT) analysis, the ORR was 38.9%. With a median follow-up time of 10.8 months, the median TTP was 5.0 months (range 3.7–6.3 months), median OS time was 11.5 months (range 9.9–13.1 months) and 1-year survival was 41.7% (95% CI 26% to 57%) and 2-year survival was 19.3% (4.4% to 34.2%).The main grade 3–4 toxicity consisted of neutropenia (55.6%) and thrombocytopenia (57.4%).Patients were required platelet transfusion in 27 cycles (12.1%) and haematopoietic growth factors support care in 56 (25.1%) cycles. No bleeding episodes were recorded. Grade 3 nausea/vomiting occurred in 5.6% and grade 1–2 skin rash occurred in 42.6%. Conclusions: Prolonged gemcitabine infusion combined with carboplatin is manageable tolerated and its efficacy is similar to that of other chemotherapeutic schemes used for NSCLC treatment. No significant financial relationships to disclose.

Survival conditions of patients with non-small cell lung cancer after chemotherapy of domestic gemcitabine combined with platinum

Curative Effect of Gemcitabine Combined with Platinum Drugs on Treatment of Advanced Squamous Carcinoma and Adenocarcinoma of Lung

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Clinical trial of advanced non-small cell lung cancer by combination of gemci-tabine and cisplatin

Gemcitabine Combined with Cisplatin As Adjuvant Chemotherapy for Non‐small Cell Lung Cancer: A Retrospective Analysis

Influences of China-Made Gemcitabine Plus Platinum Regimen on the Quality of Life among Patients with Advanced Non-Small Cell Lung Cancer

Phase II Trial of a 2-Hour Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

A Meta Analysis of Gemcitabine Plus Platinum Chemotherapy Compared with Single-agent Chemotherapy in the Treatment of Non-small Cell Lung Cancer

Gemcitabine Plus Cisplatin Combination in the Treatment of 16 Cases with Advanced Non Small Cell Lung Cancer

Clinical Study on Gemcitabine Combined with Nedaplatin or Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

[A Clinical Study on the Combination of Gemcitabine and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer].

The clinical observation of gemcitabine combined with cisplatin as second-line chemotherapy for non-small cell lung cancer

Gemcitabine Plus Oxaliplatin Combination in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

A Retrospective Analysis to Explore the Value of Gemcitabine Combined with Cisplatin As Adjuvant Chemotherapy of NSCLC

Efficacy of Gemcitabine Combined with Different Platinum Agents for Early Treatment of Advanced NSCLC

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Vinorelbine in the Treatment of Advanced Non-Small Cell Lung Cancer (Nsclc).

Efficacy of Combined Gemcitabine and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

Clinical Research for Gemcitabine Combined with Fluorouracil in the Treatment of Advanced Ovarian Cancer Patients with Taxane and Cisplatin Resistance

Effect of RRM1 and BRCA1 Expressions on Efficiency of Gemcitabine and Platinum in Patients with Advanced Non-Small Cell Lung Cancer